PRENW — Prenetics Global Limited

Summary of Prenetics Q4 and Full Year 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $36.6 million, up 457% year-over-year and 55% sequentially.
• Full Year 2025 Revenue: $92.4 million, a 480% increase from 2024.
• Q4 Gross Profit: $21.7 million, with a gross margin of 59%.
• Full Year Gross Profit: $48.9 million, a 428% increase.
• Adjusted EBITDA: Q4 loss of $2.3 million (improved by 70.4% year-over-year); full year loss of $13 million (27% improvement).
• IM8 Revenue Contribution: $27.4 million in Q4 and $60.1 million for the full year, with a gross margin of 63%.

2. Strategic Updates and Business Highlights

• Transformation: Prenetics divested noncore assets, including ACT Genomics and Insighta, to focus on consumer health, enhancing margins and liquidity.
• Liquidity Position: Total adjusted liquid assets of $171 million with zero debt, providing a strong financial foundation for growth.
• IM8 Launch: Co-founded with David Beckham, IM8 achieved a $120 million annualized revenue run rate in its first year, with a strong international presence (40% U.S., 60% international).
• Customer Acquisition: Shifted focus to quarterly subscriptions, increasing average order value from $110 to $233 and achieving an 80% subscription rate among new customers.
• Research Coverage: Initiated by ROTH Capital and Sidoti & Company, both with buy ratings and price targets of $36 and $30, respectively.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected IM8 revenue between $180 million to $200 million, representing nearly 300% year-over-year growth.
• Gross Margin Target: Approximately 60% for full year 2026.
• Adjusted EBITDA Loss: Projected between $16 million to $20 million for 2026, with a path to adjusted EBITDA profitability by Q4 2027.

4. Bad News, Challenges, or Points of Concern

• Adjusted EBITDA Loss: Despite improvements, the company still anticipates losses in the near term as it invests heavily in marketing and growth.
• Customer Acquisition Costs: While CAC has remained stable, the increase in average order value suggests that marketing efficiency needs to be closely monitored as the company scales.
• Market Competition: The health supplement market is competitive, and while IM8 has shown strong growth, sustaining this momentum will require continuous innovation and effective marketing.

5. Notable Q&A Insights

• Customer Acquisition Strategy: Discussions highlighted a focus on digital marketing and the use of AI to optimize ad performance, with a payback period of 3.4 months for customer acquisition costs.
• New Product Launches: Two new SKUs are expected by the end of Q4 2026, targeting large total addressable markets, but these are not included in the current revenue guidance.
• International Expansion: Localization efforts are underway, with expectations of a 10-15% revenue uplift in targeted markets.
• M&A Strategy: The focus remains on organic growth, with potential for strategic acquisitions if they align with business goals.

Overall, Prenetics has demonstrated remarkable growth and strategic transformation in 2025, positioning itself strongly in the consumer health market, while also acknowledging the challenges ahead as it scales operations and navigates competitive pressures.